Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
7.22
Oct 29 • 3:59 PM ET Dollar change+0.13 Percentage change(1.83%)
Aftermarket Close
6.63
Aftermarket • 7:30 PM ET Dollar change-0.59 Percentage change(-8.17%)
Index
RUT
Market Cap
370.19M
Enterprise Value
817.49M
Income
-176.80M
Sales
770.20M
Book/sh
6.65
Cash/sh
2.75
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
900
IPO
Nov 15, 2006
P/E
-
Forward P/E
6.90
PEG
8.31
P/S
0.48
P/B
1.08
P/C
2.63
P/FCF
4.31
EV/EBITDA
3.51
EV/Sales
1.06
Quick Ratio
2.95
Current Ratio
5.42
Debt/Eq
1.72
LT Debt/Eq
1.72
Option/Short
Yes / Yes
EPS (ttm)
-3.55
EPS next Y
1.05
EPS next Q
-0.39
EPS this Y
-76.50%
EPS next Y
190.99%
EPS next 5Y
0.83%
EPS past 3/5Y
- -30.38%
Sales past 3/5Y
-12.72% -13.74%
EPS Y/Y TTM
-231.68%
Sales Y/Y TTM
-9.56%
EPS Q/Q
-1477.33%
Sales Q/Q
66.29%
Insider Own
5.96%
Insider Trans
-2.73%
Inst Own
88.06%
Inst Trans
3.23%
ROA
-13.95%
ROE
-40.29%
ROIC
-19.05%
Gross Margin
47.17%
Oper. Margin
17.77%
Profit Margin
-22.96%
SMA20
7.40%
SMA50
12.25%
SMA200
-10.22%
Trades
Shs Outstand
51.30M
Shs Float
48.21M
52W High
14.06 -48.65%
52W Low
4.36 65.60%
Volatility
5.16% 5.78%
ATR (14)
0.37
RSI (14)
61.49
Beta
2.38
Rel Volume
0.56
Avg Volume
1.22M
Volume
682,401
Perf Week
15.89%
Perf Month
9.39%
Perf Quarter
0.00%
Perf Half Y
-12.27%
Perf YTD
-41.59%
Perf Year
-23.19%
Perf 3Y
261.00%
Perf 5Y
-84.85%
Perf 10Y
-73.16%
Prev Close
7.09
Price
7.22
Change %
1.83%
Consensus
Buy
Avg. Price Target
$11.00
Implied Upside
+52.4%
Analysts9incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 21, 2026Resumed
JPM logoJJP Morgan
Underweight
Dec 30, 2024Initiated
HH.C. Wainwright
Buy$15+107.8%
Aug 22, 2024Initiated
RRodman & Renshaw
Buy$16+121.6%
Mar 07, 2024Upgrade
TThe Benchmark Company
Hold → Buy$5-30.7%
Nov 20, 2023Resumed
JPM logoJJP Morgan
Underweight
Aug 29, 2023Downgrade
TThe Benchmark Company
Buy → Hold
Apr 10, 2023Upgrade
TThe Benchmark Company
Hold → Buy$22+204.7%
Mar 17, 2023Downgrade
JPM logoJJP Morgan
Neutral → Underweight$23 → $9+24.7%
Nov 10, 2022Downgrade
TThe Benchmark Company
Buy → Hold
Apr 29, 2022Downgrade
CCantor Fitzgerald
Overweight → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DONALD DEGOLYERDirectorOct 07 '26Proposed Sale7.0917,800126,120Oct 07 04:03 PM
DeGolyer Donald WDirectorOct 07 '26Sale7.0917,800126,202111,921Oct 07 03:45 PM
Williams Paul AnthonySVP, Products BusinessOct 01 '26Sale6.533,00019,590156,098Oct 05 09:16 AM
PAUL WILLIAMSOfficerOct 01 '26Proposed Sale6.533,00019,592Oct 01 04:20 PM
Williams Paul AnthonySVP, Products BusinessJul 01 '26Sale8.403,00025,200159,098Jul 02 12:57 PM
PAUL WILLIAMSOfficerJul 01 '26Proposed Sale8.403,00025,205Jul 01 04:12 PM
Dayal Sujata TyagiDirectorMay 01 '26Sale8.4013,761115,610100,563May 04 05:30 PM
DeGolyer Donald WDirectorMay 01 '26Sale8.4015,481129,994129,721May 04 05:30 PM
Katkin KeithDirectorApr 30 '26Sale8.2815,481128,18396,294May 04 05:29 PM
Zoon Kathryn CDirectorMay 01 '26Sale8.4017,202144,45379,941May 04 05:28 PM
SUJATA TYAGI DAYALDirectorMay 01 '26Proposed Sale8.4013,761115,612May 01 04:20 PM
KATHRYN ZOONDirectorMay 01 '26Proposed Sale8.4017,202144,492May 01 04:03 PM
DONALD DEGOLYERDirectorMay 01 '26Proposed Sale8.4015,481130,064May 01 04:02 PM
KEITH KATKINDirectorApr 30 '26Proposed Sale8.2815,481128,141Apr 30 04:11 PM
Williams Paul AnthonySVP, Products BusinessApr 01 '26Sale8.444,00033,76062,681Apr 03 04:05 PM
PAUL WILLIAMSOfficerApr 01 '26Proposed Sale8.444,00033,778Apr 01 04:07 PM
LOUIS W SULLIVANDirectorJan 07 '26Proposed Sale13.9925,748360,142Jan 07 04:27 PM
LOUIS W SULLIVANDirectorDec 22 '25Proposed Sale12.77104,6951,336,463Dec 22 06:22 PM
Richard RonaldDirectorDec 05 '25Option Exercise5.0225,748129,255124,165Dec 09 06:01 PM
Richard RonaldDirectorDec 05 '25Sale11.9721,984263,07798,417Dec 09 06:01 PM
RONALD RICHARDDirectorDec 05 '25Proposed Sale11.9432,848392,335Dec 05 04:04 PM
DeGolyer Donald WDirectorNov 10 '25Sale10.5417,801187,623119,858Nov 12 04:13 PM
Dayal Sujata TyagiDirectorNov 07 '25Sale10.008,55285,52088,980Nov 10 04:09 PM
DONALD DEGOLYERDirectorNov 10 '25Proposed Sale10.5417,801187,544Nov 10 04:06 PM
SUJATA TYAGI DAYALDirectorNov 07 '25Proposed Sale10.008,55285,520Nov 07 04:02 PM
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company's Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
M.B.A.Mr. Joseph C. Papa Jr.
Executive Vice President of QualityMs. Coleen Glessner
Senior Vice President of Products BusinessMr. Paul A. Williams
Senior VPMs. Jessica Perl
Vice President of CommunicationsAssal Hellmer